SCHEMBL915801

SCHEMBL915801

COc1cccc(N(c2ccccc2)c2ccc(-c3ccc(N(c4ccccc4)c4cccc(OC)c4)cc3)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.45
HSD17B2 P37059 4/20 0.45
HSD17B1 P14061 3/20 0.45
MTNR1A P48039 5/20 0.44
MTNR1B P49286 5/20 0.44
PTGES O14684 1/20 0.44
ALOX5 P09917 1/20 0.44
TRPV1 Q8NER1 1/20 0.43
ALOX15 P16050 1/20 0.43
ACHE P22303 1/20 0.42
PGR P06401 1/20 0.42
MAOB P27338 1/20 0.42
ENPP2 Q13822 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL914300 1.00 CA4 (0.45) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL19275026 1.00 CA4 (0.45) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL9763422 0.98 HSD17B2 (0.47) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL13136850 0.98 HSD17B2 (0.47) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL12463079 0.98 HSD17B2 (0.47) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL3442214 0.98 HSD17B2 (0.47) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL17372968 0.98 HSD17B2 (0.47) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL4324691 0.98 HSD17B2 (0.47) CA4HSD17B2HSD17B1MTNR1AMTNR1B
SCHEMBL9770735 0.96 HSD17B2 (0.47) HSD17B2HSD17B1MTNR1AMTNR1BALOX15
SCHEMBL10065629 0.94 CA4 (0.50) CA4HSD17B2HSD17B1MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2726460-B1 COMPOUNDS FOR THE TREATMENT OF ADDICTION GILEAD SCIENCES INC (US) 2015-09-23 EP claimed
EP-2621713-B1 DEVICE AND METHOD FOR THE PRODUCTION OF 3D STRUCTURES IN LAYERS, AND USE THEREOF FRAUNHOFER GES FORSCHUNG (DE) 2015-09-23 EP claimed
US-20090131721-A1 METHOD OF DEPROTECTION OF ALKYL ARYLAMINE ETHERS XEROX CORPORATION (US) 2009-05-21 US claimed
US-5863686-A ELECTROPHOTOGRAPHIC IMAGING PLATE COMPRISING A CHARGE GENERATING LAYER WITH DISPERSED PHOTOCONDUCTIVE PIGMENT PARTICLES, A CHARGE TRANSPORT LAYER AND A SUBSTRATE; IMPROVING SENSITIVITY XEROX CORPORATION (US) 1999-01-26 US claimed
US-20200388791-A1 ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING CAPPING LAYER AND USE VALIANT CO., LTD. 2020-12-10 US disclosed
CN-109980085-A A kind of Organnic electroluminescent device and purposes containing coating 江苏三月光电科技有限公司 2019-07-05 CN disclosed
EP-3057152-B1 OLEDS HAVING INORGANIC MATERIAL CONTAINING ANODE CAPPING LAYER LG DISPLAY CO LTD (KR) 2018-10-17 EP disclosed
EP-1624504-B1 OLEDs having inorganic material containing anode capping layer LG DISPLAY CO LTD (KR) 2016-10-12 EP disclosed
EP-1763087-B1 PHOTOELECTRIC CONVERSION DEVICES ADEKA CORP (JP) 2016-08-03 EP disclosed
EP-1385221-B1 Display device with anthracene and triazine derivtives LG DISPLAY CO LTD (KR) 2015-12-02 EP disclosed
EP-2726460-B1 COMPOUNDS FOR THE TREATMENT OF ADDICTION GILEAD SCIENCES INC (US) 2015-09-23 EP disclosed
EP-2621713-B1 DEVICE AND METHOD FOR THE PRODUCTION OF 3D STRUCTURES IN LAYERS, AND USE THEREOF FRAUNHOFER GES FORSCHUNG (DE) 2015-09-23 EP disclosed
EP-0314195-A2 Electrophotographic sensitive material MITA INDUSTRIAL CO. LTD. (JP) 1989-05-03 EP disclosed
US-4818650-A Arylamine containing polyhydroxy ether resins and system utilizing arylamine containing polyhydroxyl ether resins XEROX CORPORATION (US) 1989-04-04 US disclosed
US-4806443-A Polyarylamine compounds and systems utilizing polyarylamine compounds XEROX CORPORATION (US) 1989-02-21 US disclosed
US-4806444-A Arylamine polymers and systems utilizing arylamine polymers XEROX CORPORATION (US) 1989-02-21 US disclosed
EP-0295127-A2 Arylamine polymers XEROX CORPORATION (US) 1988-12-14 EP disclosed
EP-0295115-A2 Arylamine compounds XEROX CORPORATION (US) 1988-12-14 EP disclosed
EP-0295125-A2 Polyarylamine compounds XEROX CORPORATION (US) 1988-12-14 EP disclosed
EP-0295126-A2 Arylamine-containing polyhydroxy ether resins XEROX CORPORATION (US) 1988-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131721-A1 METHOD OF DEPROTECTION OF ALKYL ARYLAMINE ETHERS NAT1, PNMT, AADAC CA4 3488/4885HSD17B2 285/4885HSD17B1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.